Logo image of CMND

CLEARMIND MEDICINE INC (CMND) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CMND - CA1850534027 - Common Stock

2.29 USD
-0.14 (-5.76%)
Last: 12/24/2025, 8:21:46 PM
2.399 USD
+0.11 (+4.76%)
After Hours: 12/24/2025, 8:21:46 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CMND. CMND was compared to 192 industry peers in the Pharmaceuticals industry. CMND scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CMND does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMND has reported negative net income.
In the past year CMND has reported a negative cash flow from operations.
CMND had negative earnings in each of the past 5 years.
In the past 5 years CMND always reported negative operating cash flow.
CMND Yearly Net Income VS EBIT VS OCF VS FCFCMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

CMND has a Return On Assets of -101.99%. This is in the lower half of the industry: CMND underperforms 79.69% of its industry peers.
CMND has a worse Return On Equity (-378.42%) than 78.65% of its industry peers.
Industry RankSector Rank
ROA -101.99%
ROE -378.42%
ROIC N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMND Yearly ROA, ROE, ROICCMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

CMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMND Yearly Profit, Operating, Gross MarginsCMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

CMND has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CMND has more shares outstanding
The debt/assets ratio for CMND is higher compared to a year ago.
CMND Yearly Shares OutstandingCMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CMND Yearly Total Debt VS Total AssetsCMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

An Altman-Z score of 15.43 indicates that CMND is not in any danger for bankruptcy at the moment.
CMND's Altman-Z score of 15.43 is amongst the best of the industry. CMND outperforms 84.38% of its industry peers.
CMND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.43
ROIC/WACCN/A
WACCN/A
CMND Yearly LT Debt VS Equity VS FCFCMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

A Current Ratio of 1.32 indicates that CMND should not have too much problems paying its short term obligations.
CMND has a Current ratio of 1.32. This is in the lower half of the industry: CMND underperforms 75.52% of its industry peers.
A Quick Ratio of 1.32 indicates that CMND should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.32, CMND is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 1.32
CMND Yearly Current Assets VS Current LiabilitesCMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.24% over the past year.
EPS 1Y (TTM)93.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMND. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMND Price Earnings VS Forward Price EarningsCMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMND Per share dataCMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMND!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CLEARMIND MEDICINE INC

NASDAQ:CMND (12/24/2025, 8:21:46 PM)

After market: 2.399 +0.11 (+4.76%)

2.29

-0.14 (-5.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.68%
Inst Owner Change-52.3%
Ins Owners8.39%
Ins Owner Change0%
Market Cap137.38M
Revenue(TTM)N/A
Net Income(TTM)-4.05M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 128.39
P/tB 141.63
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -101.99%
ROE -378.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-350.52%
ROA(5y)-233.83%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 1.32
Altman-Z 15.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.95%
OCF growth 3YN/A
OCF growth 5YN/A

CLEARMIND MEDICINE INC / CMND FAQ

What is the fundamental rating for CMND stock?

ChartMill assigns a fundamental rating of 2 / 10 to CMND.


Can you provide the valuation status for CLEARMIND MEDICINE INC?

ChartMill assigns a valuation rating of 0 / 10 to CLEARMIND MEDICINE INC (CMND). This can be considered as Overvalued.


Can you provide the profitability details for CLEARMIND MEDICINE INC?

CLEARMIND MEDICINE INC (CMND) has a profitability rating of 0 / 10.


How financially healthy is CLEARMIND MEDICINE INC?

The financial health rating of CLEARMIND MEDICINE INC (CMND) is 6 / 10.